2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170813
    P162-0948
    		Inhibitor
    P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. P162-0948 reduces cell migration and protein expression of EMT-related proteins in A549 human alveolar epithelial cell lines. P162-0948 reduces phosphorylation of Smad, which suggests disruption of the TGF-β/Smad signaling pathway. P162-0948 is promising for research of pulmonary fibrosis.
    P162-0948
  • HY-169947
    DDO-6079
    		Inhibitor
    DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6.
    DDO-6079
  • HY-P3730
    Cdk2/Cyclin Inhibitory Peptide I
    		Inhibitor
    Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner.
    Cdk2/Cyclin Inhibitory Peptide I
  • HY-169244
    CDK-TCIP1
    		Inhibitor
    CDK-TCIP1 is a bivalent molecule linking CDK9 inhibitor SNS-032 (HY-10008) to BCL6 ligand BI3812 (HY-111381). CDK-TCIP1 potently and specifically kills BCL6-overexpressing cells with EC50 of 7.7 nM for SUDHL5 cells.
    CDK-TCIP1
  • HY-RS02384
    CDK5 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK5 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK5 Human Pre-designed siRNA Set A
    CDK5 Human Pre-designed siRNA Set A
  • HY-169246
    CDK2-IN-32
    		Inhibitor
    CDK2-IN-32 (Compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC50 of 28.52 μM.
    CDK2-IN-32
  • HY-143385
    Cdc7-IN-12
    		Inhibitor
    Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-12 shows antiproliferative activities with IC50 of 100-1000 nM in COLO205 cells. Cdc7-IN-12 has the potential for the research of cancer.
    Cdc7-IN-12
  • HY-150213A
    ODN BW001 sodium
    		Inhibitor
    ODN BW001 sodium is an oligodeoxynucleotide (ODN). ODN BW001 sodium plays a regulatory role in the proliferation and activation of osteoblast.
    ODN BW001 sodium
  • HY-161857
    Akt/mTOR-IN-1
    		Activator
    Akt/mTOR-IN-1 (Compound 8r) is an AKT/mTOR signaling pathway inhibitor exhibiting an IC50 value of 0.8 µM with anticancer activity. Akt/mTOR-IN-1 can decrease the expression of Caspase 3 and increase the expression of the autophagic protein Cyclin B1, thereby inducing cell autophagy and apoptosis. Akt/mTOR-IN-1 can be used in research related to non-small cell lung cancer (NSCLC).
    Akt/mTOR-IN-1
  • HY-172807
    p38α-IN-9
    		Inhibitor
    p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis.
    p38α-IN-9
  • HY-117988
    SNX2-1-108
    		Inhibitor
    SNX2-1-108 is a CDK8 kinase inhibitor.
    SNX2-1-108
  • HY-161690
    EF-4-177
    		Inhibitor
    EF-4-177 is an orally active and allosteric CDK2 inhibitor with the IC50 of 87 nM. EF-4-177 can disrupt spermatogenesis.
    EF-4-177
  • HY-145389
    SZ-015268
    		Inhibitor
    SZ-015268 is a CDK7 inhibitor with an IC50 of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC50s of 33, 80.56, 12.53, and 61.55 nM, respectively.
    SZ-015268
  • HY-149963
    PROTAC CDK9 degrader-6
    		Inhibitor
    PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC50s of 0.10 μM and 0.14 μM for the CDK942 and CDK955 isoforms, respectively.
    PROTAC CDK9 degrader-6
  • HY-RS02360
    Cdk13 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk13 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk13 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk13 Mouse Pre-designed siRNA Set A
    Cdk13 Mouse Pre-designed siRNA Set A
  • HY-173510
    CLK2/3-IN-1
    		Inhibitor
    CLK2/3-IN-1 (Compound 7c) is an orally active CLK2/3 inhibitor (EC50: 5.07 nM and 30.03 nM, respectively). CLK2/3-IN-1 binds to Lys193 and Lys186 of CLK2/3 via hydrogen bonds. CLK2/3-IN-1 can inhibit the proliferation of SW480 tumor cells (IC50: 163 nM). CLK2/3-IN-1 can be used to study CLK-related tumor diseases.
    CLK2/3-IN-1
  • HY-156795
    PROTAC CDK9/CycT1 Degrader-2
    		Inhibitor
    PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of CDK9, with the IC50 of 45 nM.
    PROTAC CDK9/CycT1 Degrader-2
  • HY-161978
    CDK4/6-IN-22
    		Inhibitor
    CDK4/6-IN-22 (Compound 1-A) is a CDK4 and CDK6 dual inhibitor.
    CDK4/6-IN-22
  • HY-161768
    VCC972839:01
    		Inhibitor
    VCC972839:01 is an inhibitor for cyclin dependent kinase (CDK9), with IC50 of 7 nM. VCC972839:01 inhibits the cell viability of SCLC cells in nanomolar levels. VCC972839:01 induces apoptosis through an intrinsic pathway. VCC972839:01 exhibits antitumor activity in mouse model.
    VCC972839:01
  • HY-113831
    CLK1/2-IN-3
    		Inhibitor
    LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC50 values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs.
    CLK1/2-IN-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.